Glycemion, Inc. to Market BIOSAFE's First FDA Approved Consumer Diabetes Risk Assessment...

Glycemion, Inc. to Market BIOSAFE's First FDA Approved Consumer Diabetes Risk
Assessment Available in the United States

LAKE FOREST, Ill., Jan. 22 /PRNewswire/ -- BIOSAFE Medical Technologies,
Inc. has announced the development of the first consumer test to evaluate
diabetes risk. The Diabetes Risk Assessment test will be marketed exclusively
in the United States by Glycemion, Inc. The BIOSAFE Diabetes Risk Assessment
is a two-part process comprised of an immediate fasting glucose reading and a
mail-in laboratory analysis for hemoglobin A1c, a blood glucose marker for the
previous ninety-day period. Samples for both tests can be either
professionally collected or self-collected through the use of a simple
finger-nick collection kit. Taken in combination, these two results become a
reliable indicator of diabetes or a pre-diabetes condition.
Type 2 diabetes (non-insulin dependent diabetes) affects more than
20 million Americans and is the most common form of the disease. However,
because diabetes exhibits few if any symptoms until its advanced stages,
millions more are in danger of contracting the disease and are unaware of it.
When blood glucose (sugar) levels are higher than normal, but not yet high
enough to be classified as diabetes, a condition known as pre-diabetes exists.
If discovered early, a person with pre-diabetes can avoid the disease through
education, diet, exercise, and appropriately prescribed medications.
"Diabetes is a debilitating, crippling, and life-shortening disease whose
most serious complications can be prevented with early detection. The BIOSAFE
Diabetes Risk Assessment is a common-sense approach to early detection of a
potentially dangerous condition," said Jack Maggiore, PhD, president of
BIOSAFE Laboratories, Inc. "Despite decades of medical advances for the
treatment of diabetes, millions of people remain unknowingly undiagnosed and
at risk for the disease. By making this quick, convenient and inexpensive kit
available to consumers, we are confident that those who are identified as
being in a pre-diabetic state will work with their physicians to implement
dietary and healthy lifestyle changes to avoid the onset of diabetes and its
catastrophic complications, such as heart disease, blindness, and kidney
failure."
BIOSAFE Medical Technologies, Inc. is a world leader in the development of
micro blood sample testing technology. Located in Chicago, Illinois, BIOSAFE
Laboratories, Inc. is a subsidiary of BIOSAFE Medical Technologies, Inc., and
develops, manufactures, and processes health monitoring and screening products
for the consumer, physician, health screening, occupational health,
pharmaceutical, disease-management, and medical research markets.
Glycemion, Inc. is an independent distributor of the BIOSAFE Disease Risk
Assessment and other rapid results products and marketing services.
For more information about BIOSAFE or Glycemion, Inc., contact Dana Green
at 847-234-8111, ext.122 fax 847-234-8222, or email dgreen@ebiosafe.com.
SOURCE BIOSAFE Medical Technologies, Inc.

Dana Green of BIOSAFE Medical Technologies, Inc., +1-847-234-8111, ext. 122,
fax, +1-847-234-8222, dgreen@ebiosafe.com